Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Feb 18, 2014	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Open market or private sale of non-derivative or derivative security	948	$333.50	15,900
May 13, 2013	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,086	$275.97	23,114
Nov 29, 2012	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,097	$182.20	17,737
Mar 24, 2015	Aberman Michael S SVP Strategy Investor Relation	SVP Strategy Investor Relation	Form 4	Open market or private sale of non-derivative or derivative security	1,100	$481.59	12,598
Feb 18, 2014	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Open market or private sale of non-derivative or derivative security	1,100	$332.41	16,848
Feb 24, 2015	Aberman Michael S SVP Strategy Investor Relation	SVP Strategy Investor Relation	Form 4	Open market or private sale of non-derivative or derivative security	1,103	$419.52	19,000
Dec 18, 2012	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	1,200	$24.00	11,700
Dec 18, 2012	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	1,200	--	14,964
Dec 10, 2012	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,257	$182.68	16,743
May 14, 2013	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Open market or private sale of non-derivative or derivative security	1,263	$280.40	11,800

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media